About Us

Inositec AG is developing first-in-class treatments for soft tissue calcification disorders based on its proprietary Inositune™ platform of inositol phosphate (IP6) analogs. The company’s lead programs address vascular and renal calcification disorders, including orphan indications. Inositec was founded in December 2015 as a spin-off of ETH Zurich.


Inositune Platform

Our drug discovery platform is based on inositol hexaphosphate, (IP6). By selectively replacing phosphate groups on IP6, we are able to obtain molecules with more favorable drug-like properties…
Learn more >


Product Pipeline

By changing the physico-chemical properties of IP6 through chemical modifications, Inositec is building a pipeline of novel drugs, initially targeting cardiovascular and renal calcification disorders.
Learn more >



Inositec has an extensive drug discovery platform based on analogs of inositol. Initially, Inositec will pursue development of its lead compounds through preclinical proof of concept before partnering certain drug candidate and discovery assets…
Learn more >


Our news section offers you a simple and easy way to know what is going on in our company.